摘要
目的为证明钙调蛋白的抑制剂三氟拉嗪和抗P-糖蛋白单克隆抗体(JSB-1)能协同逆转人肾癌的天然多药耐药(MDR)性。方法我们对经过病理证实36例肾透明细跑癌采用RT-PCR方法检测mdr-1表达水平,高表达的为耐药组,无或低表达的为敏感组,给予阿霉素与三氟拉嗪和JSB-1处理,并采用MTT法评价细胞毒作用,流式细胞仪检测细胞内ADR浓度聚集。结果三氟拉嗪(TFP)和JSB-1对肿瘤细胞无明显的细胞毒作用;但具有逆转肾癌对ADR的耐药,并且在耐药(P-gp过表达MDR)的肾癌细胞中,效果更明显(P<0.01)。结论三氟拉嗪和JSB-1可作为肾癌化疗的辅助用药,联合应用效果更佳,它的低毒副作用使其具有应用价值和可行性。
Purpose To illustrate that the trifluoperazine (TFP)which is the calmodulin inhibitor and anti-P-gp monoclonal antibody (JSB-1)can reverse multidrug resistance (MDR)of the human kidney cancer. Methods We put 36 cases of kidney cancer into two groups: resistance drug and no-resistance drug based on the expression lever of Mdr-1 gene which was analyzed with reverse transcription poly-merase chain reaction (RT-PCR) ,and then treated them with adriamycin (ACR), anti-P-gp monoclonal antibody (JSB-1)and trifluoperazine (TFP),after that,we examined the cytotoxicity and accumulation by MTT test and the flow cytometry. Result The TFP and JSB-1 are no obvious effect of the cytotoxicity to tumor cell but they can reverse multidrug resistance of the kidney cancer and increase the ADR' s cytotoxicity to the tumor cell,especially in the resistance drug group (P<0.01) ,whereas it also can increase the density of the ADR in the cell,especially in joint use of trifluoperazine (TFP)and JSB-1. Conclusion The trifluoperazine (TFP) and JSB-1 can be used as supplementary drug in the chemotherapy to the kidney cancer,joint use is better. Their low toxin and side effect make them practical and valuable.
出处
《中国血液流变学杂志》
CAS
2003年第1期15-17,共3页
Chinese Journal of Hemorheology
基金
本课题为苏州市科技发展计划基金资助。
